SG Americas Securities’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

SG Americas Securities’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-898	Closed	-$24K	–	3380
2023 Q1	$24K	Buy	+898	New	+$41.8K	﹤0.01%	3141
2021 Q4	–	Sell	-755	Closed	-$151K	–	3911
2021 Q3	$151K	Buy	+755	New	+$180K	﹤0.01%	3434
2020 Q3	–	Sell	-442	Closed	-$127K	–	3610
2020 Q2	$127K	Buy	+442	New	+$130K	﹤0.01%	3209
2015 Q2	–	Sell	-37	Closed	-$317K	–	2892
2015 Q1	$317K	Buy	+37	New	+$323K	﹤0.01%	1659

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

SG Americas Securities's EIGR Position: Q2 2023 in Review

SG Americas Securities sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 898 shares — an estimated $24K sold.

SG Americas Securities first reported a position in EIGR in Q1 2015 and held it in 4 quarters. The position peaked at $317K in Q1 2015. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

SG Americas Securities reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
SG Americas Securities sold 898 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $24K.
SG Americas Securities first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2015 and held it in 4 quarters.
SG Americas Securities's Eiger BioPharmaceuticals, Inc. position peaked at $317K in Q1 2015.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on SG Americas Securities's 13F filing for Q2 2023, filed 10 Jul 2023.